Comment from OncoLens

Summary: OncoLens, a healthcare technology company, supports the pilot program by providing specific recommendations on using AI to improve patient recruitment and site feasibility in early-phase oncology trials. They argue that AI can bridge the gap in trial access for community and rural settings by identifying eligible patients from unstructured clinical data and providing more accurate, data-driven site selection.